Healthcare
EBOS Group Limited(EBOSY)
Live Price
Offline$26.00
+0.00% today
1Y Change
-38.01%
Window
Jun 26, 2025 โ Jun 15, 2026
- Market Cap
- $1.35B
- Revenue Growth
- -8.3%
- EPS Growth
- -23.6%
- Dividend Yield
- 5.4%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
EBOS Group Limited (EBOSY) is a Healthcare stock with a market cap of $1.35B and listed on OTC. The stock last traded around $26.00 and down 38.0% across the available one-year price window (Jun 26, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -8.3%, EPS growth of -23.6%, a dividend yield of 5.4%. What stands out right now is revenue -8.3%, EPS -23.6%, free cash flow +37.5% with operating margin 3.0% and ROIC 5.7%. The dividend matters to the case here, with a current yield around 5.4%. Valuation is more restrained than many high-expectation growth names at P/E 9.1 and price/sales 0.2. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines EBOSY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-8.3% vs +7.6% peer median
Operating Margin
Below sector median
+3.0% vs +19.4% peer median
P/E
Below sector median
9.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 17, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -8.3% and EPS is at -23.6%, with operating margin around 3.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 5.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 17, 2026 | โ | +0.0% | +0.0% | +7.6% |
2025 Aug 27, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Feb 19, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
EBOSY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EBOSY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EBOSY Max Drawdown
-42.27%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EBOSY and SPY.
Company Overview
EBOS Group Limited
Other OTC
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company supplies health and wellness products to public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and provides pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers allografts solutions; healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
- Leadership
- Adam Luke Hall
- IPO Date
- May 11, 2017
- Employees
- 5.2k
- Street Address
- 737 Bourke Street
- Mailing
- Docklands, VIC, 3008
- Region
- Docklands, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9918 5555
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 9.1
- EV/EBITDA
- 7.7
- Price/Sales
- 0.2
- Price/Book
- 0.7
Growth
- Revenue
- -8.3%
- EPS
- -23.6%
- Free Cash Flow
- +37.5%
Profitability
- Gross Margin
- 7.2%
- Operating Margin
- 3.0%
- Net Margin
- 1.8%
- ROE
- 6.2%
- ROIC
- 5.7%
Balance Sheet
- Debt/Equity
- 0.82
- Current Ratio
- 1.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.